Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarker driven umbrella trial of crenolanib in combination with ivosidenib, enasidenib, venetoclax, vyxeos and/or salvage chemotherapy in FLT3 mutant AML
    Meeting Abstract

    Daver, N.; Goldberg, A. D.; DiNardo, C. D.; Kadia, T. M.; Wang, E. S.; Stone, R. M.; Zhang, H.; Messahel, B.
    Blood (2020)

    Fulltext@MSK | Save
  • Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): Activity in CML chronic phase patients failing TKI therapies including ponatinib
    Meeting Abstract

    Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Khattry, N.; Rathnam, K.; Apperley, J.; Deininger, M. W.; de Lavallade, H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The Prosid study: Evaluating efficacy and safety of intravenous immunoglobulin (IVIG) 10% in primary infection prophylaxis in patients with chronic lymphocytic leukemia-study design
    Meeting Abstract

    Cornely, O.; Mato, A.; Robak, T.; Mellinghoff, S.; Lavrova, T.
    Blood (2020)

    Fulltext@MSK | Save
  • Outcome by mutation status and line of treatment in optic, a dose-ranging study of 3 starting doses of ponatinib in patients with CP-CML
    Meeting Abstract

    Cortes, J. E.; Apperley, J.; Hochhaus, A.; Mauro, M. J.; Rousselot, P.; Sacha, T.; Talpaz, M.; Chuah, C.; Lipton, J. H.; Deininger, M. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: Primary efficacy and safety results from a phase 1 trial
    Meeting Abstract

    Cortes, J. E.; Hughes, T. P.; Mauro, M. J.; Hochhaus, A.; Rea, D.; Goh, Y. T.; Janssen, J.; Steegmann, J. L.; Heinrich, M. C.; Talpaz, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Longitudinal molecular profiling in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib
    Meeting Abstract

    Choe, S.; Wang, H.; Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; Mims, A. S.; Prince, G. T.; Watts, J. M.; Fan, B.; Nejad, P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Impact of comorbidities on response outcomes in patients with chronic myeloid leukemia in chronic phase treated with first-line dasatinib versus imatinib: Exploratory post hoc analysis of DASISION
    Meeting Abstract

    Breccia, M.; Mauro, M. J.; Jabbour, E.; Saglio, G.; Jimenez-Velasco, A.; le Coutre, P. D.; DeGutis, I.; Khan, W.; Sy, O.; Swanink, R.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): Final 5-year results from the BFORE trial
    Meeting Abstract

    Brümmendorf, T. H.; Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; Clark, R. E.; le Coutre, P. D.; Garcia-Gutiérrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Trial in progress: A phase I trial of BTX-A51 in patients with relapsed or refractory AML or high-risk MDS
    Meeting Abstract

    Ball, B. J.; Stein, A. S.; Borthakur, G.; Murray, C.; Kook, K.; Chan, K. W.; Stein, E. M.
    Blood (2020)

    Fulltext@MSK | Save
  • Safety and efficacy of maintenance treatment following allogeneic hematopoietic cell transplant in acute myeloid leukemia and myelodysplastic syndrome - A systematic review and meta-analysis
    Meeting Abstract

    Bewersdorf, J. P.; Tallman, M. S.; Cho, C.; Zeidan, A. M.; Stahl, M.
    Blood (2020)

    Fulltext@MSK | Save